

OTC Markets

Welcome to the OTCQB podcast, where we shine a spotlight on our OTCQB venture market companies. I'm your host, Cody Maldonado, client relations for EMEA at OTC Markets Group. Joining us today is Thomas Fahrhoefer, Chairman and President of CS Diagnostics, which trades on our OTCQB market under ticker symbol CSDX. CS Diagnostics is a medical sector leader committed to advancing patient care through innovative solutions. Thomas, it's a pleasure to have you on the podcast.

Thomas Fahrhoefer

Yeah, pleasure is mine.

OTC Markets

So, you know, to sort of kick things off, can you provide an overview of CS Diagnostics Corp and show the company's mission and vision in the medical and wellness product space?

Thomas Fahrhoefer

Yeah, the CS Diagnosis Corp is part of our CES group, where we develop products, medical devices, medicines, and food supplements. So, most of the R&D, research and development, and manufacturing take place in Germany and Europe, where we have a strong presence. And also, we have a strong presence in the MENA region, Middle East, North Africa. And so, we are well-positioned CS diagnosis Corp to leverage two decades of experience and success. So, our entry into the US market and OTC QB listing was the most logical step to expanding our global reach. So, our vision is to secure, improved health care globally by focusing on prevention and better therapy outcomes with less side effects. And our mission is to use the latest technology and innovations in biochemistry to improve longevity for everyone and vitality around the world.

OTC Markets

And you know, what sort of inspired the development of your flagship product, CS Protect Hydrogel, and how does it address unmet needs in prostate cancer treatment?

Thomas Fahrhoefer

Cancer treatment itself is a huge topic globally and radiation oncology is one of the main options in cancer treatments. And a hydro gel is a liquid which we inject

between the healthy tissue and the cancerous tissue, which becomes a solid after injection, a solid gel throughout the entire radiation treatment process. So, it stays there in volume and in positioning stable. And with CS Protect Hydrogen, the physicians are able to increase their dosages of radiation so the and also to reduce the numbers of fractions. So, it's much, much more efficient in terms of the treatment. It is far more convenient for the patients as they only require five or 10 fractions instead of 30 or 40. So, hydrogel is so important that we have thought it was developed and successfully used -- It is already developed and successfully used in the past in prostate cancer treatments. So, when our new generation is developed to have it used in many more cancer treatments. And that's why this is the reason why Hydrogel OCS, Protect Hydrogel has a valuation of 960 million US dollars.

OTC Markets

Wow, you know, and with decades of experience, as you mentioned earlier in designing and distributing wellness and medical products, how has the company evolved to meet the challenges of the modern healthcare landscape?

Thomas Fahrhoefer

Yeah, we are well experienced in the healthcare field. We see we have a long, many, many, many years experience in the market, research, product development, manufacturing, distribution. So, of course we know the environment of the physicians in the hospitals and also, the stakeholders such as governments and health insurance companies very well. We are always focused on being ahead of everyone in the field, which also includes artificial intelligence applications nowadays. And also, we have another advantage. We are built on a very lean company structure, which remains very flexible, adaptive to markets. We can adapt to changes and demands. So, this is definitely a big a USP of our company structure.

OTC Markets

And what are some of the key areas for growth for CS Diagnostics Corp? And, how does the company plan to expand its product offerings or markets in the next three to five years?

Thomas Fahrhoefer

Yeah, the focus already of yeah -- The big focus is on prevention, prevention meaning substantial diagnostics and protection. The specialization is pretty much on cancer treatments. This also goes along with stress reduction, improving

metabolism, strengthening immune system. So, this all This all serves longevity, a vital in health life. So, they are our main focus.

OTC Markets

And what role does the US market play in the company's growth strategy? And how are you adapting to the competitive landscape?

Thomas Fahrhoefer

Well, of course, the US market is one of the leading markets when it comes to health care and medical developments. So, it was obvious part of our global development strategy. So, the U - And also the US market is open for innovation, provides an excellent platform for global development and naturally investor opportunities. And if it comes to competitors, actually, we are not concerned about competitors. So, we are welcoming-- we are welcoming any player in the field because we are leading the field. We are leading the landscape.

OTC Markets

And are there any upcoming launches or partnerships in the US that you're particularly excited about? You know, how do you see these contributing to your long-term goals?

Thomas Fahrhoefer

Yeah. We have a large pipeline of very exciting partnerships in the US. So, we are really excited to enter the market, which will be released um in the upcoming weeks and months. So, it's going to be very exciting, very, very large partnerships. And we also will be launching new exciting products through CS Diagnostic Scope in 2025. So, my advice would be to everyone who's listening to get in touch with us and follow us for updates.

OTC Markets

Definitely. And, you know, when we talk about listing in the United States, why was listing on the OTCQB venture market a strategic decision for CS Diagnostics Corp?

Thomas Fahrhoefer

Yeah, open up the US market, of course, you know entering into the US markets and also raise capital for very exciting and innovative products, which the world needs. So, all this is definitely part of our strategy, and we are happy to go that route.

OTC Markets

And you know, the company really emphasizes on enhancing patient outcomes through innovation. How would you measure the impact of your products on patient care and what advancements are you currently working on?

Thomas Fahrhoefer

Yeah, basically our proof is always measured on the actual outcomes of improvements in patient treatments, the results, and we have a daily communication and feedback loops with our clients, the leading research universities, which of course also helps us to improve and adapt very quickly. Since all of our work has to be medically proven, we continuously run post-market studies and have very close contact and ongoing communication with our users.

OTC Markets

And as the company continues to grow, what message would you like to share with your stakeholders and investors about the future of the company?

Thomas Fahrhoefer

We will definitely always focus on innovation and lead the market in prevention and specializing in cancer treatments. So, we are right in the center of the growing, the high potential healthcare markets, exactly where any of the investors wants to be.

OTC Markets

Well, thank you again, Thomas, for taking the time to speak with me today. You know you can find CS Diagnostics trading on our OTCQB venture market under the ticker symbol CSDX.

**This is an autogenerated transcript and may contain typos.*